Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. - Abstract - Europe PMC
wave1presentation Foreign Issuer Report 6-K
Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
FDA grants priority review to Takeda's dengue vaccine – PharmaLive
ABOUT DENGUE AND TAKEDA'S DENGUE VACCINE CANDIDATE (TAK-003)
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents | NEJM
The Lancet on Twitter: "NEW—Tetravalent dengue vaccine (TAK-003) was well tolerated and efficacious against symptomatic #dengue in children aged 4-16 years regardless of serostatus before immunisation: a randomised, placebo-controlled, phase 3 trial
Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate ( TAK-003) Granted Priority Review by U.S. Food and Drug Administration - Headlines of Today
Cross-reactivity of T cell responses following TAK-003... | Download Scientific Diagram
Takeda dengue vaccine TAK-003 provides continued protection against dengue fever through 4.5 years in trial
CONTRIBUTING TO THE FIGHT AGAINST DENGUE
Takeda's Dengue Vaccine Manufacturing Plant, Singen, Germany
Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial - The Lancet
Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate ( TAK-003) Granted Priority Review by U.S. Food and Drug Administration
Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003) | PLOS Neglected Tropical Diseases
Global First Approval For Takeda's Dengue Vaccine, In Indonesia :: Scrip
Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. - Abstract - Europe PMC
Potential Impact of Takeda's Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
Drug Overview: TAK-003 - Research and Markets
Takeda's dengue vaccine TAK-003 shows efficacy through 4.5 years in trial | Seeking Alpha
TAK-003 - News, Articles etc. - European Pharmaceutical Review
TAK-003 induces functional DENV cross-reactive cellular immmunity | Immunopaedia
